Form 4: Immunome Director Carol Schafer Receives Significant Stock Option Grant

Immunome Inc. director Carol Schafer was granted 18,864 stock options with an exercise price of $9.57, vesting quarterly over one year, aligning her interests with long-term shareholder value.

Summary

• Immunome Inc. (IMNM) director Carol Schafer was granted 18,864 stock options.
• The options have an exercise price of $9.57 per share.
• These options vest in four quarterly installments, commencing from June 10, 2025, until the one-year anniversary thereafter.
• Vesting is contingent upon Ms. Schafer's continuous service with the company.
• The options are exercisable and expire on June 9, 2035.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is generally a positive signal of alignment and retention, indicating continued commitment from the board. It's a standard compensation practice, so not overwhelmingly positive, but certainly not negative.

Positives

• The grant of stock options to Director Carol Schafer aligns her interests with those of shareholders, incentivizing long-term performance and value creation.
• The options have a long expiration date of June 9, 2035, providing ample time for potential value realization if the company's stock price appreciates.

Negatives

• No specific negative information is disclosed in this Form 4 filing, as it primarily reports a routine compensation grant.

Risks

• The value of the stock options is subject to the future performance of Immunome Inc.'s common stock; there is no guarantee that the stock price will exceed the exercise price of $9.57.
• Vesting of the options is contingent on continuous service, meaning the options could be forfeited if the director's service ceases before full vesting.

Future Outlook

The document does not provide a general future outlook for the company, but the grant of long-term options suggests an expectation of continued service and potential future stock appreciation for the director.

Industry Context

This Form 4 filing is a routine disclosure of insider compensation in the biotechnology or pharmaceutical industry, where equity grants are a common component of executive and director remuneration to align interests with long-term company performance and shareholder value.

Comparison to Industry Standards

• The grant of stock options to a director is a standard practice in corporate governance across various industries, including biotechnology.
• The specific number of options and exercise price would typically be benchmarked against peer companies of similar size and stage (e.g., other small-to-mid cap biotech firms like Xencor (XNCR), Arvinas (ARVN), or Blueprint Medicines (BPMC)) to ensure competitive compensation and alignment with market practices, though this document does not provide such comparative data.

Stakeholder Impact

• **Shareholders:** The grant of options aligns the director's interests with shareholders, as the options gain value only if the stock price increases, potentially incentivizing decisions that enhance shareholder value.
• **Employees:** No direct impact on employees is mentioned, but such compensation practices are part of a broader corporate compensation philosophy.

Next Steps

• The options will vest in four quarterly installments, commencing from June 10, 2025, subject to continuous service.
• The director may choose to exercise these options at any time after vesting and before the expiration date of June 9, 2035, assuming the stock price is above the exercise price.

Key Dates

Keywords

Immunome Inc., IMNM, Form 4, Insider Transaction, Stock Options, Director Compensation, Equity Grant, Beneficial Ownership